For example, zenocutuzumab, a bispecific HER2xHER3 antibody, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of Neuregulin 1-positive (NRG1+) non-small cell lung cancer and pancreatic ductal adenocarcinoma [16]. The gene discussed is NRG1; the disease is pancreatic ductal adenocarcinoma.